Sustained Mechanical Release of Dexamethasone Sodium Phosphate from a Foldable Capsular Vitreous Body

Abstract

FCVB can sustainably and mechanically release DexP by capsule apertures in a time-dependent and dose-dependent manner in addition to serving as a vitreous substitute.

A study of the dexamethasone sodium phosphate release properties from a periocular capsular drug delivery system

“…Four-hundred microliter liquid in each cup was aspirated at 0.5, 1, 2, 4, 8, 24 and 48 h for determination. The concentration was determined by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS), according to the Liu et al (2010).…”

“…It has successfully released dexamethasone sodium phosphate (DEXP), siRNA-PKCa, 5-fluorouracil and levofloxacin through the 300-nm-mini apertures in the surface sustainedly (Liu et al, 2010;Chen et al, 2011;Lin et al, 2011;Zheng et al, 2012). In order to avoid vitrectomy accompanied by foldable capsular vitreous body and to reduce the direct disturbance of the intraocular environment of the eye, we develop a periocular capsular DDS, which can be implanted to the posterior Tenon's sac adjacent to the sclera by means of the same craft technique.…”

Evaluation of 5-fluorouracil released from a foldable capsular vitreous body in vitro and in vivo

“…Our previous studies demonstrated that FCVB was combined research for a vitreous substitute and DDS [15,20], then showed it was flexible, effective, and safe over a 3-month implantation time in patients with severe retinal detachments in clinical trials [16]. However, we found that in multiple-center clinical trials the FCVB capsule reattached the retina with a platform for the formation of a flat scar that may influence ultimate visual acuity.…”

“…The ideal intravitreal DDS is a kind of material that not only achieves an intravitreal DDS but also functions as a vitreous tamponade agent [14]. Fortunately, we have previously certified that FCVB could serve as a DDS that could provide the mechanically sustained release of dexamethasone sodium phosphate (DexP) [15], levofloxacin, and protein kinase Cα (PKCα) (data not shown). Moreover, in a clinical trial of FCVB over a three-month implantation period, it was shown to be a flexible, effective, and safe vitreous substitute in the treatment of severe retinal detachment [16].…”

Age-related cataract and macular degeneration: Oxygen receptor dysfunction diseases

“…Oxygen isotope would be injected into the vitreous cavity or injected into FCVB as a long-term sustained oxygen release system in the eye [21]. This will allow for observation of the metabolism and distribution of the oxygen.…”